Pulmonary Disease Clinical Trial
Official title:
xrAI - Improving Quality and Efficiency in Chest Radiograph Interpretation
Verified date | September 2020 |
Source | 1QB Information Technologies Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
xrAI (pronounced "X-ray") serves as a clinical assistance tool for trained clinical
professionals who are interpreting chest radiographs. The tool is designed as a quality
control and adjunct, limited, clinical decision support tool, and does not replace the role
of clinical professionals. It highlights areas on chest radiographs for review by an
interpreting clinician.
The objective of this study is to utilize machine learning and artificial intelligence
algorithms (xrAI) to improve the quality and efficiency in the interpretation of chest
radiographs by family doctors, nurse practitioners, emergency medicine physicians,
internists, pulmonologists, and radiologists.
The hypothesis is that the addition of xrAI's analysis will reduce inter-observer variability
in the interpretation of chest radiographs and increase participants' sensitivity, recall,
and accuracy in pulmonary abnormality screening.
Status | Completed |
Enrollment | 28 |
Est. completion date | April 21, 2020 |
Est. primary completion date | April 21, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Family doctors currently practicing at a site within Saskatchewan Health Authority - Nurse practitioners currently practicing at a site within Saskatchewan Health Authority - Emergency medicine physicians currently practicing at a site within Saskatchewan Health Authority - Internists currently practicing at a site within Saskatchewan Health Authority - Pulmonologists currently practicing at a site within Saskatchewan Health Authority - Radiologists currently practicing at a site within Saskatchewan Health Authority Exclusion Criteria: - Physicians not currently practicing at a site within Saskatchewan Health Authority. - Physicians currently practicing at a site within Saskatchewan Health Authority as neither family doctors, nurse practitioners, emergency medicine physicians, internists, pulmonologists, nor radiologists. |
Country | Name | City | State |
---|---|---|---|
Canada | 1QB Information Technologies Inc | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
1QB Information Technologies Inc. | Saskatchewan Health Authority - Regina Area |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of abnormalities identified divided by number of total of images analyzed (accuracy) | Accuracy is defined as the ratio of the images where the physician's prediction matched the labels of the dataset. Accuracy= (TP+FP) / (TP+FP+TN+FN) TP (true positives) = cases interpreted as abnormal that are abnormal; FP (false positives) = cases wrongly interpreted to be abnormal; TN (true negatives) = cases correctly interpreted to be normal; FN (false negatives) = abnormal cases wrongly interpreted as normal. |
Time needed to analyze 500 images. Participants will be asked to completed the exercise within 2 weeks. | |
Primary | Number of true abnormalities identified divided by the total of abnormalities identified (precision) | Precision is defined as the probability of a radiograph being abnormal if a physician makes the determination that it is abnormal. Precision= TP / (TP+FP) TP (true positives) = cases interpreted as abnormal that are abnormal; FP (false positives) = cases wrongly interpreted to be abnormal; TN (true negatives) = cases correctly interpreted to be normal; FN (false negatives) = abnormal cases wrongly interpreted as normal. |
Time needed to analyze 500 images. Participants will be asked to completed the exercise within 2 weeks. | |
Primary | Number of true abnormalities identified divided by the sum of true abnormalities identified and abnormalities missed (recall) | Recall is defined as the probability of a physician catching an abnormality in an image if one exists (based on the labels of the dataset). Recall= TP / (TP+FN) TP (true positives) = cases interpreted as abnormal that are abnormal; FP (false positives) = cases wrongly interpreted to be abnormal; TN (true negatives) = cases correctly interpreted to be normal; FN (false negatives) = abnormal cases wrongly interpreted as normal. |
Time needed to analyze 500 images. Participants will be asked to completed the exercise within 2 weeks. | |
Secondary | Mean of physician accuracy (as defined in outcome 1) | Investigators will calculate the mean of the accuracy of all participants in a group and the mean of the accuracy of all participants across all the groups. | Time needed to analyze 500 images. Participants will be asked to completed the exercise within 2 weeks. | |
Secondary | Mean of physician precision (as defined in outcome 2) | Investigators will calculate the mean of the precision of all participants in a group and the mean of the precision of all participants across all the groups. | Time needed to analyze 500 images. Participants will be asked to completed the exercise within 2 weeks. | |
Secondary | Mean of physician recall (as defined in outcome 3) | Investigators will calculate the mean of the recall of all participants in a group and the mean of the recall of all participants across all the groups. | Time needed to analyze 500 images. Participants will be asked to completed the exercise within 2 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
Active, not recruiting |
NCT02504697 -
DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
|
||
Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
Terminated |
NCT00524095 -
Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis
|
Phase 2 | |
Completed |
NCT00210249 -
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
|
||
Completed |
NCT00023114 -
p450 Mediated Lung Toxicity
|
N/A | |
Recruiting |
NCT06056882 -
Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
|
||
Completed |
NCT03994848 -
Incentive Spirometry Prehabilitation Study
|
N/A | |
Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
Withdrawn |
NCT05100160 -
Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)
|
Phase 3 | |
Completed |
NCT03229473 -
Fall Risk Assessment in COPD
|
||
Recruiting |
NCT04767074 -
A Non-pharmacological Cough Control Therapy
|
N/A | |
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT04996693 -
On Dose Efficiency of Modern CT-scanners in Chest Scans
|
N/A | |
Recruiting |
NCT04996173 -
Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)
|
N/A | |
Completed |
NCT04601545 -
The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method
|
N/A | |
Recruiting |
NCT03937583 -
Screening for Cancer in Patients With Unprovoked VTE
|
Phase 4 | |
Recruiting |
NCT02862418 -
Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)
|